On December 18, 2023, the Minister of Health announced the creation of the Canadian Drug Agency. According to the announcement, the Canadian Drug Agency (CDA) “will provide the dedicated leadership and coordination needed to make Canada's drug system more sustainable and better prepared for the future, helping Canadians achieve better health outcomes.” It will be built from the Canadian Agency for Drugs and Technologies in Health (CADTH), in partnership with provinces and territories. The CDA will build on CADTH’s mandate and functions, and will expand them, including improving appropriate prescribing and use of medications, and increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and life sciences regulatory law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Ontario pilot program and pCPA new negotiation pathway aim to expedite access to breakthrough cancer treatments
The Ontario government and the pan-Canadian Pharmaceutical Alliance (pCPA) announced separate initiatives in October 2025, both aimed to accelerate patient access to breakthrough cancer treatments app...Read More -
pCPA introducing revisions to pathway for non-complex drug negotiations
The pan-Canadian Pharmaceutical Alliance (pCPA) recently announced it is formalizing and introducing revisions to the Targeted Negotiation Process (TNP).Read More -
Ontario proposes legislation to regulate preferred provider networks
Following two public consultations with stakeholders, the Government of Ontario (Ministry of Finance) is moving forward with legislation to regulate preferred provider networks (PPNs).Read More
